Drug
TJ004309
TJ004309 is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
1(25%)
Results Posted
100%(1 trials)
Phase Distribution
Ph phase_1
2
50%
Ph phase_2
1
25%
Phase Distribution
2
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
Phase 2Efficacy & side effects
1(33.3%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(1)
Completed(1)
Other(2)
Detailed Status
unknown2
Active, not recruiting1
Completed1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 12 (66.7%)
Phase 21 (33.3%)
Trials by Status
active_not_recruiting125%
unknown250%
completed125%
Recent Activity
1 active trials
Showing 4 of 4
completedphase_2
A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors
NCT05001347
active_not_recruitingphase_1
A Phase I/II Study of TJ004309 for Advanced Solid Tumor
NCT04322006
unknown
Expanded Access Study of TJ004309 in Patients With Advanced or Metastatic Cancer
NCT04869501
unknownphase_1
Study of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic Cancer
NCT03835949
Clinical Trials (4)
Showing 4 of 4 trials
NCT05001347Phase 2
A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors
NCT04322006Phase 1
A Phase I/II Study of TJ004309 for Advanced Solid Tumor
NCT04869501
Expanded Access Study of TJ004309 in Patients With Advanced or Metastatic Cancer
NCT03835949Phase 1
Study of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic Cancer
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4